A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Registry ID

EUCTR2017-001294-16

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Alkermes, Inc.

Start date

2017-09-22

Completion date

2019-06-27

Last update

2026-08-16

Conditions

• Relapsing-Remitting Multiple Sclerosis

Summary

Evaluate the safety of ALKS 8700 and the GI tolerability of ALKS 8700 and DMF in adult subjects with RRMS

Locations

• , , Poland
• , , Germany

Related clinical trials

• A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

View on source registry